Google
×

Tigilanol tiglate

Medication
Tigilanol tiglate, sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based mast cell tumors. The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog's skin, in... Wikipedia
People also ask
Oct 3, 2022 · Tigilanol tiglate is a natural product diterpenoid in clinical trials for the treatment of a broad range of cancers.
Tigilanol tiglate (USAN; ), sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell ...
Welcome to STELFONTA (tigilanol tiglate injection) · STELFONTA®: An innovative and effective treatment for Mast Cell Tumors in dogs · STELFONTA® removes 75% of ...
An innovative and effective treatment for mast cell tumors (MCTs) in dogs. 87% of dogs had a complete response after 1 or 2 treatments.
Nov 15, 2021 · We use the data to introduce the concept of tigilanol tiglate-mediated margins as a comparator with surgical margins to allow assessment and ...
Oct 26, 2022 · Tigilanol tiglate is an approved veterinary pharmaceutical (STELFONTA®) for the intratumoural treatment of non-metastatic MCTs in Australia, the ...
Background Tigilanol Tiglate (TT) is a novel small molecule under development for local treatment of solid tumours via intratumoral (I.T.) injection.
Stelfonta is a cancer veterinary medicine used in dogs to treat mast cell tumours that are not suitable for surgery and that have not spread to other parts ...
Feb 16, 2024 · The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.
Sep 9, 2020 · Tigilanol tiglate is a novel small molecule approved as a veterinary pharmaceutical in Europe for intratumoural treatment of non-metastatic, ...